|Numéro de publication||US5679374 A|
|Type de publication||Octroi|
|Numéro de demande||US 08/367,422|
|Date de publication||21 oct. 1997|
|Date de dépôt||30 déc. 1994|
|Date de priorité||30 déc. 1993|
|État de paiement des frais||Payé|
|Autre référence de publication||CA2138873A1, CA2138873C, DE69400428D1, DE69400428T2, EP0661036A1, EP0661036B1|
|Numéro de publication||08367422, 367422, US 5679374 A, US 5679374A, US-A-5679374, US5679374 A, US5679374A|
|Inventeurs||Chantal Fanchon, Alain Ribier, Jean-Thierry Simonnet, Evelyne Segot|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (2), Citations hors brevets (2), Référencé par (63), Classifications (48), Événements juridiques (4)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
1. Field of the Invention
The present invention relates to compositions for the cosmetic or dermatological treatment of imperfections or complaints of the skin, including the scalp. It relates more particularly to an anti-acne composition, comprising at least one active agent which is conveyed via at least two distinct types of lipid vesicles. The present invention also relates to a method for the anti-acne treatment of the skin.
2. Discussion of the Background
Acne is one of the diseases usually affecting, and to varying degrees, the juvenile population between the ages of 15 and 30. Ache is due essentially to the increased production, at puberty, of androgens such an testosterone, which stimulate the sebaceous glands in order to raise the production of sebum. Hyperkeratinization of the follicular duct is observed simultaneously, creating in the pilosebaceous follicle an environment which in rich in nutrients for the bacterial flora and which especially promotes the proliferation of diphtheroid anaerobic germs such as the Propionibacteria (acnes, granulosnm, avidum) and, consequently, inflammation of the skin.
Acne treatments which are generally used are keratolytic agents such as salicylic acid or the derivatives thereof, for the purpose of removing dead or hyperkeratinized skin, and antibacterial agents.
Many examples are known of cosmetic or dermatological compositions intended for treating the skin, which have one or more active agents that are suitable for treating the skin and which are encapsulated in lipid spherules or vesicles (also known an liposomes).
Lipid spherules or vesicles are understood to refer to particles formed of a membrane consisting of one or more concentric lamellae, these lamellae containing one or more bimolecular layers of amphiphilic lipids encapsulating an aqueous phase. The aqueous phase may contain water-soluble active substances and the bimolecular layers of amphiphilic lipids may contain lipophilic active substances.
These spherules generally have a mean diameter of between 10 nm and 5000 nm.
Among the many documents published regarding this matter, there may be mentioned the French Certificate of Addition 2,408,387 which describes a composition based on aqueous dispersions of ionic or nonionic lipid spherules encapsulating at least one active substance. More precisely, this document describes compositions containing at least two dispersions of spherules containing different active agents, for the purpose of obtaining a mixed system, that is to say a system in which a first dispersion of spherules containing a first type of active substance in combined with a second dispersion of spherules containing another type of active substance, which enables the two types of substances to act simultaneously at the time of treatment and possibly to obtain a synergistic effect which would not be produced if these two types of substances were made to act successively and separately.
Skin disorders of the acne type concern both an attack on the surface layers of the skin and a related impairment of the deeper layers of the epidermis and of the dermis.
It is well known that the skin consists of surface layers, the stratum corneum, and of deep layers, the live epidermis and the dermis. However, specific delivery of such an active agent into the surface layers and, simultaneously, of the same or another active agent into the deep layers, is not known from the prior art.
Thus, there remains a need for treating acne which treats both the stratum corneum and the deep layers of the skin. There also remains a need for compositions useful in such methods.
Accordingly, it is one object of the present invention to provide a novel method for the treatment of acne.
It is another object of the present invention to provide a method for treating acne which simultaneously treats the surface layers and deep layers of the skin.
It is another object of the present invention to provide novel compositions useful in such methods.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compositions which comprise
(a) first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and which contain at least one active agent chosen from antimicrobial agents, antiseptic agents, anti-inflammatory agents, anti-seborrhoeic agents, antibiotics, retinol (vitamin A) and the derivatives thereof, for treating these deep layers; and
(b) a second dispersion of lipid vesicles which are capable of penetrating into the surface layers of the skin and which contain at least one active agent chosen from keratolytic agents, protective agents, moisturizing agents and antioxidants, for treating these surface layers, are effective for the simultaneous anti-acne treatment of the surface layers of deep layers of the skin.
The inventors have now developed cosmetic and/or dermatological anti-acne compositions, which allow the simultaneous action of two different active agents, and which furthermore allow these active agents to act in different areas of the skin, that is to say in the surface layers and in the deep layers of the skin, thereby very markedly enhancing the effectiveness of these compositions and the complementary or synergistic effect of the anti-acne active agents used.
The inventors have also developed cosmetic or dermatological anti-acne compositions, which enable the same active agent to act simultaneously in the surface layers and in the deep layers of the skin, providing a more complete and therefore a more effective treatment of the disorder from which it is suffering.
According to a specific embodiment, the active agents contained in the first dispersion of vesicles and in the second are the same.
The Applicant has used a means of classifying vesicles which enables a person skilled in the art readily to select lipid vesicles capable of conveying the active agent to the deep layers of the skin, known as vesicles with deep-down action, and those capable of conveying the active agent to the surface layers of the skin, known as vesicles acting at the surface.
This classification is made on the basis of the diffusion constant D of a probe introduced into the vesicles. This probe is N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidyl)-N,N-dimethyl-N-hydroxyethylammonium iodide (ASL), of formula (I): ##STR1##
Vesicles for which the diffusion constant D of the probe into the stratum corneum is >1×10-7 cm2 s-1 are vesicles which are capable of penetrating into the deep layers of the skin.
Vesicles for which the diffusion constant D of the probe into the stratum corneum is <1×10-7 cm2 s-2 are vesicles which are capable of conveying the active agent to the surface layers of the skin.
The vesicles of the first type, the so-called vesicles with deep-down action, are generally in the fluid state at room temperature (about 20° C.), and those of the second type, the so-called vesicles acting at the surface, are generally in the gelled state at room temperature. The means of recognizing the state of the vesicles consists in determining the phase (fluid-gel lamellar) transition temperature of the main lipid constituting the membrane thereof, by differential thermal analysis (DTA).
Other characteristics of these vesicles relate to their ability to deliver the active agent to a greater or lesser depth in the skin. This is particularly the case for the degree of encapsulation.
Glucose is a labelling agent conventionally used for this type of determination (see in particular Liposomes a practical approach by R. R. C. New, IRL Press, pp. 125-136 (1990)).
The degree of encapsulation is expressed as the volume of glucose solution encapsulated in the vesicles, measured in μl relative to the unit weight (mg) of the lipids constituting the membrane. This degree of encapsulation is determined immediately after the step of separation of the free glucose and of the encapsulated glucose (To), an well as twenty-four hours after this separation (T24 hours).
The difference between these two successive determination illustrates the permeability of the vesicles with respect to the encapsulated glucose, which may also be referred to as their encapsulation potential.
The first type of vesicles (delivering the active agent into the deep layers of the skin) has a high encapsulation potential for the small water-soluble molecules which are conventionally modelled by glucose, this encapsulation potential being maintained for at least 24 hours. The second type of vesicles (delivering the active agent into the surface layers of the skin) does not retain glucose in the encapsulated state for the same amount of time.
The main lipids constituting the vesicles of the first type (deep delivery of the active agent) are composed of at least one linear and saturated fatty chain of length ranging from 16 to 30 carbon atoms, such an hydrogenated phospholipids (from plants or from eggs), saturated synthetic phospholipids such as dipalmitoylphosphatidylcholine, and polyol alkyl ethers or polyol alkyl eaters containing one, two or three fatty chains per molecule. These lipide are used alone or as a mixture.
The main lipids constituting the vesicles of the second type (active agent delivered at the surface) are chosen in particular from the group comprising ionic lipids, especially such as natural plant- or egg-based phospholipids, containing unsaturated fatty chains having from 16 to 30 carbon atoms; nonionic lipids such an polyol alkyl ethers or polyol alkyl esters containing one or more fatty chains per molecule, including at least one fatty chain with a length of less than 16 carbon atoms, such as lauryl polyglyceryl-6-cetearyl glycol ether, described in detail in French Patent Application FR 92-09603 filed by L'Oreal.
It is possible, in a known manner, to incorporate into the lipid phase constituting the lipid membrane of the vesicles, at least one additive chosen from the group formed of sterols (phytosterols, cholesterol or polyoxyethylenated phytosterols); long-chain alcohols, diols and triols (phytanetriol), long-chain amines and the quaternary ammonium derivatives thereof; phosphoric esters of fatty alcohols and the alkali metal (Na or K) salts thereof, such an dicetyl phosphate, sodium dicetyl phosphate, alkyl sulfates (sodium cetyl sulfate), alkali metal salts of cholesterol sulfate or of cholesterol phosphate, the sodium salt of phosphatidic acid, and lipoamino acids and the salts thereof, such as the sodium acylglutamates.
Examples of vesicles of the first category (delivering the active agent into the deep layers of the skin) which may be mentioned are vesicles obtained from the following lipids (CTFA name):
A/cholesterol/casein lipoamino acid, especially in a 45/45/10 weight ratio (where A is a triglyceryl cetyl ether marketed by the company Chimex under the name Chimexane NL);
B/cholesterol/dicetyl phosphate, especially in a 60/35/5 weight ratio (where B is a mixture of triglyceryl mono-, di- and tricetyl ether, marketed by the company Chimex under the name Chimexane NT);
Span 40 (from ICI, or Sorbitan palmitate)/cholesterol/sodium acylglutamate (marketed under the same HS11 by the company Ajinomoto), especially in a 47.5/47.5/5 weight ratio;
PEG 8 stearate/cholesterol/sodium acylglutamate, especially with a 47.5/47.5/5 weight ratio (where PEG 8 stearate is polyethylene glycol containing 8 units of ethylene oxide, marketed by the company Unichema under the name PEG 400 stearate);
PEG 8 stearate/cholesterol/phytanetriol/sodium acylglutamate, especially with a 47.5/20/27.5/5 weight ratio;
Hydrogenated lecithin/polyoxyethylenated phytosterol containing 5 units of ethylene oxide, especially in a 60/40 weight ratio;
Polyoxyethylenated methylglucose distearate containing 20 units of ethylene oxide/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio (the distearate being, for example, that sold under the name Glucam E 20 distearate by Amerchol);
A/cholesterol/dicetyl phosphate, especially with a 47.5/47.5/5 weight ratio;
Diglyceryl distearate (for example that sold by Nihon under the name Emalex DS G2)/cholesterol/sodium acylglutamate, in a 45/45/10 weight ratio;
Sucrose mono- and distearate (for example that sold by Grillo under the Grilloten PSE 141 G)/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio;
Tetraglyceryl tristearate (for example that sold by Nikkol under the name Tetraglyn 3S)/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio.
Examples of vesicles of the second type (delivering the active agent into the surface layers of the skin) which may be mentioned are vesicles obtained from the following lipids:
Natipide II (soya lecithin/ethanol/water in a 20/16/64 weight ratio, marketed by Nattermann);
C (soya lecithin/cholesterol/propylene glycol in a 60/20/20 weight ratio, marketed by Nattermann under the name NAT 50 PG);
D/dimyristyl phosphate, especially in a 95/5 weight ratio (where D is a lauryl polyglyceryl-6-cetearyl glycol ether marketed by the company Chimex under the name Chimexane NS).
Table I below gives, for some of the vesicles obtained using the above lipids, the diffusion constant D for ASL in the stratum corneum and in the epidermis/dermis, as well as the degree of encapsulation of glucose and the phase transition temperature of the main lipid constituting the membrane. The diffusion constant was measured for an encapsulated ASL concentration of 0.35% by weight relative to the total weight of the composition.
TABLE I__________________________________________________________________________ Diffusion coefficient Degree of D in 10-7 cm2 s-1 encapsulation Phase Proportions in the in the of glucose in transition % by weight stratum epidermis/ μl/mg temperatureRef. LIPID SYSTEMS (mg) corneum dermis To T24h in °C.__________________________________________________________________________ 1st type - deep down1 A/cholesterol/casein 45/45/10 42 5 7.5 6.8 50 lipoamino acid (67.5/67.5/15)2 B/cholesterol/dicetyl 60/35/5 58 2 11.1 11.1 54 phosphate (90/52.5/7.5)3 Span 40/cholesterol/ 47.5/47.5/5 42 2 13.8 13.8 50 sodium acylglutamate (71.25/71.25/7.5)4 PEG 8 stearate/ 47.5/47.5/5 42 2 14.4 14.4 55 cholesterol/sodium (71.25/71.25/7.5) acylglutamate5 PEG 8 stearate/ 47.5/20/27.5/5 8.3 2.5 4.1 3.0 55 cholesterol/phytanetriol/ (71.25/30/ sodium acylglutamate 41.25/7.5)6 Hydrogenated lecithin/ 60/40 8 2 6.0 4.8 80 polyoxyethylenated (90/60) phytosterol 2nd type - surface7 Sunflower lecithin 100 0.3 0.2 1.6 0 <0 (150)8 Natipide II (soya 20/16/64 0.4 0.2 0.4 0 <0 lecithin/ethanol/water) (30/24/96)9 C (soya lecithin/ 60/20/20 0.25 0.1 1.8 0 <0 sterols/propylene glycol) (90/30/30)10 D/dimyristyl phosphate 95/5 0.3 0.2 2.0 0 14 (142.5/7.5)__________________________________________________________________________
Measurement of the diffusion constant D is carried out by combining two methods using a paramagnetic probe, ASL: one-dimensional and periodic electron paramagnetic resonance (EPR), on the one hand, and EPR kinetic imaging, on the other hand. These two methods are respectively described in the articles "Evaluation of liposomes as drug carriers into the skin by one-dimensional EPR imaging" by V. Gabrijelcic et al., International Journal of Pharmaceutics, vol. 62, pp. 75-79, Elsevier (1990), and "Liposome entrapped molecules penetration into the skin measured by nitroxide reduction kinetic imaging" by V. Gabrijelcic et al., Periodicum Biologorum, vol. 93, No. 2, pp. 245-246 (1991).
Measurement of the degree of encapsulation is carried out as described in Liposomes a practical approach by R. R. C. New, IRL Press, pp. 125-136 (1990) cited previously, and that of the phase transition temperature is carried out as described above.
Advantageously, several active agents are used simultaneously in each type of vesicles, these active agents having the same function and/or imparting to the skin, at the surface and deep down, the same type of effect; the agents active at the surface and the agents with deep-down action are thus complementary.
The active agents with deep-down action and the agents active at the surface which may be used in the present invention are those which are conventionally used in the cosmetic or dermatological field.
The active agents with deep-down action are in particular chosen from retinol (vitamin A) and the derivatives thereof, such as retinol acetate, propionate or palmitate; tretinoin and isotretinoin.
Antiseptic agents which may be mentioned are triclosan; hexamidine and the salts thereof, such as hexamidine diisothionate; chlorhexidine and the salts thereof, such an chlorhexidine diacetate or digluconate; azelaic acid and the salts thereof, such an the acetate.
Anti-seborrhoeic agents which may be mentioned are octopirox, and zinc salts such as zinc cysteate, and zinc oxide.
Antimicrobial agents which may be mentioned are clindamycin and other antibiotics of erythromycin type; N,N-dimethyl-N-(2-hydroxyethyl)ammonium 5-n-dodecanoylsalicylate, abbreviated to DHADS; katoconazole and other antifungal agents such an clotrimozol.
As non-steroidal anti-inflammatory active agents which may be used in the invention, there may be mentioned ASPIRIN® (acetylsalicylic acid), OXYCAMS®, and β-glycyrrhetinic acid.
As steroidal anti-inflammatory active agents which may be used in the invention, there may be mentioned hydrocortisone and the derivatives thereof, such an hydrocortisone acetate, phosphate or butyl acetate.
The agents active at the surface are advantageously chosen from keratolytic agents, for instance 5-n-octanoylsalicylic acid, salicylic acid, α-hydroxy acids such an lactic acid, glycolic acid or tartaric acid, or from fruit; antioxidants, for instance nitroxide radicals, anti-squalene-peroxidation active agents such as tocopherol and the derivatives thereof, sequestering agents and glucosyl quercetin; protective agents, for instance sunscreen agents; moisturizing agents, for instance polyols such as glycerine.
Screening agents which may be mentioned as a guide are: p-aminobenzoic acid and the derivatives thereof (glyceryl, ethyl and isobutyl esters); anthranilates (such as the o-aminobenzoate or the alkyl esters); salicylates; cinnamic acid derivatives; dihydroxycinnamic acid derivatives; trihydroxycinnamic acid derivatives; hydrocarbons (stilbene); dibenzalacetone and benzalacatophenone; coumarin derivatives; hydroxy- or methoxy-substituted benzophenones; tannic acid and the derivatives thereof; benzophonones and any other sunscreen agent conventionally used in the cosmetic and/or dermatological field, such as benzylidenecamphor, benzene-1,4-di(3-methylidene-10-camphorsulfonic) acid or alternatively 4-(3-methylidenecamphor)phenyltrimethylammoniummethyl sulfate, as well as mixtures thereof, 2-ethylhexyl 2-cyano-3,3'-diphanylacrylate or alternatively dibenzoylinethane.
Pigments or nanopigments may also be used, especially those of zinc oxide and/or of titanium oxide (TiO2, ZnO2).
As nitroxide radicals which may be used in the invention, there may be mentioned 2,2,6,6-tetramethylpiperidine 1-oxide, 4-hydroxytetramethylpiperidine 1-oxide, docylcyclohexane and N-tert-butyl-alpha-phenylnitrone.
The agents active at the surface and the agents with deep-down action may be present in an amount from 0.02 to 10% by weight, preferably 0.1 to 5% by weight, based on the total weight of the composition.
The compositions according to the present invention may be provided in all the pharmaceutical forms normally used for topical application, such as aqueous gels, emulsions, lotions, ointments, sera and, more particularly, vesicle-dispersed oil droplets such as those described in French patents FR-A-2,485,921 and FR-A-2,490,504.
As is known, in addition to the vesicles, a vegetable oil, mineral oil, silicone-containing oil or synthetic oil which is dispersed in an aqueous phase, and also hydrophilic adjuvants such an gelling agents, antioxidants, preserving agents, opacifying agents, lipophilic adjuvants such as essential oils and fragrances, pigments and fillers, may be found in the compositions of the present invention, as described in the above French patents. For example, polyethylene beads may be added to provide a cleaning action (scrub). The dispersed oil may be present in an amount of from 2 to 40% by weight, preferably 5 to 20% by weight, based on the total weight of the composition, and the adjuvants may be present in a total amount of from 0.1 to 10% by weight, preferably 1 to 5% by weight, based on the total weight of the composition.
The invention also relates to a use of the composition defined above for the preparation of an ointment intended to treat acne and to a process for treating acne, by in applying this composition to the skin.
The vesicles of both the first and second types suitably comprise 1 to 90% by weight, preferably 5 to 70% by weight, more preferably 5 to 20% by weight, of the total weight of the composition.
The relative amounts of the vesicles of the first and second types in the present compositions are suitably:
10 to 90% by weight of the vesicles of the first type, and
90 to 10% by weight of the vesicles of the second type, preferably:
30 to 70% by weight of the vesicles of the first type, and
70 to 30% by weight of the vesicles of the second type,
based on the total weight of the vesicles of the first and second types.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
In all of the Examples, the term "qs 100 g" means that that ingredient is added in a amount sufficient to make the total amount of all ingredients equal 100 g.
A. production of lipid vesicles containing ASL:
The constituent lipids of the wall of the vesicles are weighed and dissolved in 10 ml of methanol. The alcoholic solution is then transferred into a 50 ml round-bottomed flask with a ground joint, which in subsequently placed on a rotary evaporator such that the contents are thermostatted at a temperature of 30° C. The evaporation in continued until a dry film of lipids is deposited on the wall of the flank.
3 ml of an aqueous 0.01 molar solution of ASL are then added to the flask, which is subsequently shaken by hand for about 10 minutes, either at room temperature (20° C.) for the vesicles of Table I of reference Nos. 7 to 10, or at a temperature of 50° C. for the vesicles of reference Nos. 1 to 6 of Table I. The medium is then left to equilibrate at room temperature for 2 hours, after which the dispersion is placed in a dialysis bag and in contact with 500 ml of distilled water. Dialysis taken place overnight. The next day, the water in changed and the dialysis is continued for a further 4 hours.
A cotton thread 0.3 mm thick is then soaked in the vesicle dispersion and then placed in contact with a section of skin cut from a pig's ear which has been freshly taken from an abattoir intended for food supply.
The ear sample taken is rinsed with water and cut into slices 1 mm thick, 5 mm wide and 10 mm long and then placed in a maintenance cell. Measurements of the diffusion of ASL into the skin are made in the 24 hours following the taking of the skin sample.
B. Production of the cosmetic composition:
1. Production of vesicles of the first type (diffusing deep down).
The vesicles (with deep-down action) are prepared according to a common method for co-fusion of the various membranes constituents chosen (see Table I). Thus, the membrane constituent having the lowest melting point Tm is melted. The other membrane constituents are added thereto and the mixture is then homogenized with moderate stirring and is finally partially hydrated, while maintaining the melting temperature Tm defined above.
An aqueous solution of at least a first active agent for the deep-down treatment is added to the paste obtained. The mixture is stirred with a turbine for 1 hour and 30 minutes in order to hydrate fully, while maintaining the temperature Tm. One or more other active agents for the deep-down treatment are added to the reaction medium, homogenization is carried out and the temperature of the medium is lowered to room temperature (20° C.).
2. Production of vesicles of the second type diffusing at the surface).
An aqueous solution of one (or more) second active agent for the surface treatment is introduced, at room temperature (20° C.) and with simple stirring, into the chosen mixture of constituents which are to form the membrane of the vesicles acting at the surface (see Table I). Vesicles acting at the surface encapsulating the second active agent acting at the surface are thus obtained.
3. Production of the "double-liposome" composition.
The fatty phase (the oils) of the composition is added to the medium containing the vesicles with deep-down action, and it is dispersed (at room temperature) with stirring. The reaction medium obtained is then mixed with that containing the vesicles acting at the surface. The adjuvants, such as preserving agents, a gelling agent which may be neutralized if necessary with a base (triethanolamine or sodium hydroxide), and fragrances, etc., are then optionally added.
The product obtained is in the form of a soft and smooth white cream which may be used in the cosmetic and/or dermatological field for the treatment of acne on the face and/or body.
The invention also relates to the use of the composition defined above and to a process for treating acne, consisting in applying a composition as defined above to the human face and/or body. The invention also relates to the use of this composition for the preparation of a dermatological ointment intended for the treatment of acne.
Specific examples of cosmetic compositions in accordance with the invention are given below.
______________________________________Preparation A: Liposomes with deep-down action:Triglyceryl cetyl ether 8.1 gCholesterol 8.1 gDHADS (active agent) 1.8 gMethylparaben (preserving agent) 0.1 gGlycerine 12.0 gDemineralized water qs 100 gPreparation B: Liposomes acting at the surface:Chimexane NS/dimyristyl phosphate 20.0 gin a 95/5 weight ratioSalicylic acid (active agent) 2.0 gGlycerine 15.0 gMethylparaben (preserving agent) 0.2 gDemineralized water qs 100 gDouble-liposome composition:Preparation A 33.3 gPreparation B 25.0 gVegetable oil 3.0 gVolatile silicone oil 4.5 gTriclosan (active agent) 0.2 gPreserving agents 0.3 gCarboxyvinyl polymer (gelling agent) 0.9 gSodium hydroxide 1.8 gDemineralized water qs 100 g______________________________________
The cream obtained may be applied daily in order to attenuate, or even to eradicate, comedones caused by acne.
This cream differs from that of Example 1 in that 5-n-octanoylsalicylic acid is used as the agent acting at the surface, in place of salicylic acid.
______________________________________Preparation A: Liposomes with deep-down action:Triglyceryl cetyl ether 7.6 gCholesterol 7.6 gSodium acylglutamate 0.8 gTretinoin (active agent) 0.2 gMethylparaben (preserving agent) 0.1 gGlycerine (active agent) 15.0 gDemineralized water qs 100 gPreparation B: Liposomes acting at the surface:Chimexane NS 20.0 gGlycerine (active agent) 15.0 gGlycolic acid (active agent) 3.0 gMethylparaban (preserving agent) 0.2 gDemineralized water qs 100 gDouble-liposome composition:Preparation A 25.0 gPreparation B 25.0 gHydrogenated isoparaffin 3.0 gCarboxyvinyl polymer (gelling agent) 0.9 gSodium hydroxide 1.8 gPreserving agents 0.6 gAntioxidants 0.2 gDemineralized water qs 100 g______________________________________
This application is based on French Patent Application 93-15865 filed on Dec. 30, 1993, which is incorporated herein by reference in its entirety.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|US4217344 *||29 déc. 1977||12 août 1980||L'oreal||Compositions containing aqueous dispersions of lipid spheres|
|EP0571063A1 *||7 déc. 1990||24 nov. 1993||Schering Aktiengesellschaft||Pharmaceutical preparations|
|1||Lasch et al. "How deep do intact liposomes penetrate into human skin?", J. q controlled release 18, #1, Jan. 1992 pp. 55-58.|
|2||*||Lasch et al. How deep do intact liposomes penetrate into human skin , J. q controlled release 18, 1, Jan. 1992 pp. 55 58.|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US5866148 *||23 juin 1997||2 févr. 1999||Societe L'oreal S.A.||Photoprotective compositions comprising mutually incompatible oily dispersed phases|
|US5985925 *||9 sept. 1998||16 nov. 1999||Societe L'oreal S.A.||Photoprotective/cosmetic compositions comprising UV-sunscreens/dialkyl tartrates|
|US6022896 *||10 sept. 1998||8 févr. 2000||Chesebrough-Pond's Usa Co.||Petroselinic acid as an anti-irritant in compositions containing alpha-hydroxy acids|
|US6042841 *||15 mars 1999||28 mars 2000||Unilever Home & Personal Care Usa Division Of Conopco, Inc.||Cosmetic method of treating skin|
|US6183774||17 août 1999||6 févr. 2001||Collaborative Laboratories, Inc.||Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts|
|US6444647||7 avr. 2000||3 sept. 2002||The Procter & Gamble Company||Skin care compositions containing combination of skin care actives|
|US6521237||3 juin 1999||18 févr. 2003||Johnson & Johnson Consumer Companies, Inc.||Skin care composition|
|US6544531||9 nov. 1999||8 avr. 2003||Johnson & Johnson Products, Inc.||Skin care composition|
|US6555143||28 févr. 2001||29 avr. 2003||Johnson & Johnson Consumer Products, Inc.||Legume products|
|US6750229||27 juil. 1999||15 juin 2004||Johnson & Johnson Consumer Companies, Inc.||Methods for treating skin pigmentation|
|US6773627||4 déc. 2003||10 août 2004||Children's Hospital Research Foundation||Cubic liquid crystalline compositions and methods for their preparation|
|US6818226||24 juil. 2001||16 nov. 2004||Acrux Dds Pty. Ltd.||Dermal penetration enhancers and drug delivery systems involving same|
|US6861060||21 avr. 2000||1 mars 2005||Elena Luriya||Personal care formulations|
|US7078048 *||9 mai 2002||18 juil. 2006||The Regents Of The University Of Michigan||Method and compositions for treating rosacea|
|US7094422||20 août 2003||22 août 2006||Acrux Dds Pty Ltd.||Topical delivery of antifungal agents|
|US7252816 *||29 mars 2006||7 août 2007||Dow Pharmaceutical Sciences||Topical acne vulgairs medication with a sunscreen|
|US7285544 *||18 nov. 2004||23 oct. 2007||Bernstein Eric F||Use of nitroxides in treating skin disease|
|US7285570||17 avr. 2003||23 oct. 2007||The Procter & Gamble Company||Compositions and methods for regulating mammalian keratinous tissue|
|US7326408 *||27 juin 2007||5 févr. 2008||Dow Pharmaceutical Sciences||Topical acne vulgaris medication with a sunscreen|
|US7387789||8 sept. 2006||17 juin 2008||Acrux Dds Pty. Ltd.||Transdermal delivery of non-steroidal anti-inflammatory drugs|
|US7396526||5 mai 2000||8 juil. 2008||Johnson & Johnson Consumer Companies, Inc.||Skin care composition|
|US7416756||10 sept. 2003||26 août 2008||Eastman Chemical Company||Process for the recovery of a phytolipid composition|
|US7438203||20 janv. 2004||21 oct. 2008||Acrux Dds Pty Ltd||Dermal penetration enhancers and drug delivery systems involving same|
|US7491412||12 mai 2004||17 févr. 2009||Eastman Chemical Company||Process for the recovery of a phytolipid composition|
|US7795302||30 nov. 2005||14 sept. 2010||The Regents Of The University Of Michigan||Use of compositions for treating rosacea|
|US7879823||6 juil. 2004||1 févr. 2011||Johnson & Johnson Consumer Companies||Topical anti-cancer compositions and methods of use thereof|
|US7897144||26 janv. 2007||1 mars 2011||Johnson & Johnson Comsumer Companies, Inc.||Compositions containing legume products|
|US8016810||23 juin 2004||13 sept. 2011||Transpharma Medical Ltd.||Transdermal delivery system for cosmetic agents|
|US8053000||5 juin 2006||8 nov. 2011||Dr. Reddy's Laboratories Limited||Compositions for drug delivery|
|US8063097||14 août 2007||22 nov. 2011||The Procter & Gamble Company||Compositions and methods for regulating mammalian keratinous tissue|
|US8071075||5 oct. 2007||6 déc. 2011||Acrux Dds Pty Ltd.||Dermal penetration enhancers and drug delivery systems involving the same|
|US8318786||14 août 2008||27 nov. 2012||The University Of Chicago||Plant pathogen resistance|
|US8603539||17 oct. 2011||10 déc. 2013||Dr. Reddy's Laboratories Limited||Compositions for drug delivery|
|US8617578||12 mars 2012||31 déc. 2013||L'oreal||Compositions containing topical-active agents and pentyleneglycol|
|US8685440 *||1 août 2007||1 avr. 2014||Daewoong Co., Ltd||Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same|
|US20040079921 *||4 déc. 2003||29 avr. 2004||Lynch Matthew Lawrence||Cubic liquid crystalline compositions and methods for their preparation|
|US20040081684 *||20 août 2003||29 avr. 2004||Monash University||Topical delivery of antifungal agents|
|US20040091493 *||25 nov. 2002||13 mai 2004||Coletica||Active ingredients stimulating type 2 and/or type 3 human beta-defensins and cosmetic or pharmaceutical compositions containing such active ingredients|
|US20040146469 *||20 janv. 2004||29 juil. 2004||Monash University||Dermal penetration enhancers and drug delivery systems involving same|
|US20040175347 *||4 mars 2003||9 sept. 2004||The Procter & Gamble Company||Regulation of mammalian keratinous tissue using hexamidine compositions|
|US20040176273 *||17 févr. 2004||9 sept. 2004||The Procter & Gamble Company||Regulation of mammalian keratinous tissue using hexamidine compositions|
|US20040191206 *||7 avr. 2004||30 sept. 2004||Curtis Cole||Methods for reduction of inflammation and erythema|
|US20040208903 *||17 avr. 2003||21 oct. 2004||Robinson Larry Richard||Compositions and methods for regulating mammalian keratinous tissue|
|US20040213754 *||26 janv. 2004||28 oct. 2004||Cole Curtis A.||Method for cleansing sensitive skin using an alkanolamine|
|US20050043283 *||22 août 2003||24 févr. 2005||L'oreal S.A.||Compositions containing topical active agents and pentylene glycol|
|US20050051419 *||10 sept. 2003||10 mars 2005||Zima George Chester||Process for the recovery of a phytolipid composition|
|US20050053712 *||12 mai 2004||10 mars 2005||Zima George Chester||Process for the recovery of a phytolipid composition|
|US20050124593 *||18 nov. 2004||9 juin 2005||Bernstein Eric F.||Use of nitroxides in treating skin disease|
|US20050238730 *||11 nov. 2002||27 oct. 2005||Agnes Le Fur||Compositions comprising an ethanolamine derivative and organic metal salts|
|US20060018852 *||1 août 2005||26 janv. 2006||L'oreal||Compositions containing topical active agents and pentylene glycol|
|US20120156147 *||29 juin 2010||21 juin 2012||Natura Cosmeticos S.A.||Cosmetic composition; skin treatment kit; method for treating oily or mixed skin or acned skin|
|CN102366407A *||14 sept. 2011||7 mars 2012||海南灵康制药有限公司||Clindamycin palmitate hydrochloride liposome solid preparation|
|CN102366407B||14 sept. 2011||20 mars 2013||海南灵康制药有限公司||Clindamycin palmitate hydrochloride liposome solid preparation|
|DE10251709A1 *||6 nov. 2002||12 févr. 2004||Coletica||Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3 und kosmetische oder pharmazeutische Zusammensetzungen, die solche Wirkstoffe enthalten|
|DE10251709B4 *||6 nov. 2002||27 nov. 2008||Engelhard Lyon S.A.||Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3|
|DE10251709C5 *||6 nov. 2002||24 févr. 2011||Engelhard Lyon S.A.||Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3|
|EP1358876A1 *||30 avr. 2002||5 nov. 2003||Cognis Iberia, S.L.||Microcapsules containing anti-acne agents|
|EP1596876A1 *||12 févr. 2004||23 nov. 2005||Euro-Celtique S.A.||Use of pvp-iodine liposomes for treatment of acne|
|WO1999022703A1 *||18 oct. 1998||14 mai 1999||Lurident Ltd||Improved personal care formulations|
|WO2001085129A2 *||4 mai 2001||15 nov. 2001||Johnson & Johnson Consumer||Skin care composition|
|WO2003092664A1 *||22 avr. 2003||13 nov. 2003||Carmen Arias||Micro-capsules with anti-acne active ingredients|
|WO2006133131A1 *||6 juin 2006||14 déc. 2006||Vakati Venkat Arvind||Compositions for drug delivery|
|WO2007126915A1 *||28 mars 2007||8 nov. 2007||Dow Pharmaceutical Sciences||Topical acne vulgaris medication with a sunscreen|
|Classification aux États-Unis||424/450, 424/401, 514/859, 514/846|
|Classification internationale||A61K8/63, A61K8/00, A61K8/41, A61K8/86, A61K9/127, A61K8/14, A61K8/27, A61K8/30, A61K8/36, A61K8/44, A61K8/19, A61K8/49, A61K8/368, A61Q17/00, A61K9/133, A61K8/39, A61K8/34, A61P17/12, A61P31/04, A61K8/04, A61P17/18, A61K8/92, A61K8/60, A61Q19/00, A61K31/575, A61P29/00, A61K8/37, A61K45/00, A61K8/85, A61K8/67|
|Classification coopérative||Y10S514/859, Y10S514/846, A61K8/368, A61K8/14, A61K9/127, A61K8/671, A61Q19/00, A61K8/347|
|Classification européenne||A61Q19/00, A61K8/67C, A61K8/14, A61K8/368, A61K9/127, A61K8/34F|
|16 mai 1995||AS||Assignment|
Owner name: L OREAL, FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FANCHON, CHANTAL;RIBIER, ALAIN;SIMONNET, JEAN-THIERRY;AND OTHERS;REEL/FRAME:007478/0381;SIGNING DATES FROM 19950321 TO 19950404
|29 mars 2001||FPAY||Fee payment|
Year of fee payment: 4
|23 mars 2005||FPAY||Fee payment|
Year of fee payment: 8
|25 mars 2009||FPAY||Fee payment|
Year of fee payment: 12